Stem Cell Review: Tissue Repair (EP10)
Quick Links
Description
You are Watching:
Stem Cell Review: Tissue Repair (EP10)
Rebuilding tissue with stem cell products requires bioengineering. Bob Langer of MIT helps us understand the bio-engineer's role in (a) the isolation, purification, and expansion of cells (b) the encapsulation - immuno-isolation (c) the creation of scaffolds to guide the cell development, and (d) the monitoring of stem cell activity and clinical benefit. Bob shares clinical stories including heart tissue repair and spinal cord repair. He then touches on the regulatory aspect of stem cells and devices, which together form combination products. In his future outlook, professor Bob Langer describes cellular therapy for tissue repair, having the potential to bring revolutionary treatments to patients, such as rebuilding organs - something traditional drugs could never accomplish.
This is the Episode 10 of the Stem Cell Review, aired on December 17th, 2009
Related Videos
Organogenesis' Apligraf: Allogeneic Cell Based Wound Healing; FDA Approved and Shipping! (EP10) (9:03)
<all>Organogenesis CEO Geoff McKay presents one of the leading cell therapy companies today. Built through revenues over the past 5 years, Organogenesis' lead product, Apligraf, is FDA approved, and currently being sold to wound care centers around the world. Organogenesis' pipeline also includes a tendon repair product (in partnership with Integra LifeSciences), as well as the first product approved by the FDA to stimulate soft tissue regeneration in the mouth (receding gum). Finally, Geoff highlights the business model, according to which Organogenesis is responsible for the product from development and manufacturing to commercialization. Organogenesis has it's own commercial team.
Organogenesis' Apligraf: Allogeneic Cell Based Wound Healing;...
Stem Cell Review: AutoImmune Diseases & Blood Disorders (EP9) ()
<all>What are Hematopoietic Stem Cells (HSCs)? Where can we we find them? Where do they originate? Hanna Mikkola of UCLA helps us understand HSC, the current limitations in cell expansion that are limiting clinical use, as well as the direction of the efforts being made today to overcome this challenge (better harvesting, in vitro expansion, better engraftment, generating HSCs from human embryonic stem cells or induced pluripotent stem cells). Hanna reviews some of the clinical indications in which HSCs are being used, including leukemia, inherited immune deficiencies, aplastic anemia, and autoimmune diseases. New discoveries in the placenta show it is a niche in which HSCs can proliferate without differentiating, one we can study to understand HSCs expansion. Finally, Hanna gives a future outlook for HSCs.
Stem Cell Review: AutoImmune Diseases & Blood Disorders (EP9)
Stem Cell Review: Stem Cells & Diabetes (EP8) ()
<all>Alan Lewis of the Juvenile Diabetes Research Foundation distinguishes type 1 and type 2 diabetes, and continues to explain how stem cells are being used today to develop new treatments for type 1 diabetes (a.k.a. juvenile diabetes). Human embryonic stem cells (hESC) are being differentiated to the beta (insulin producing) cells that type 1 diabetics lack, and are being transplanted , in animal models. Since type 1 diabetes is an auto-immune disease, the transplanted cells must be protect from destruction by the immune system. Currently, researchers are working towards that goal with encapsulating technologies and a "gentle" immuno-modulation. In order to treat a diabetic patient, access to an unlimited number of cells is necessary. Alan compares embryonic stem cells, adult stem cells, and iPS as source of cells. And finally, in a future outlook, Alan comments on the FDA's concern for safety, the risk of creating a tumor, artificial pancreas (as an alternative approach), and cell therapy's potential to CURE diseases.
Stem Cell Review: Neural Stem Cells and CNS Disorder (EP7) (12:47)
<all>What is a neural stem cell? How can they help treat neurological disorders such as Alzheimer's disease, Parkinson's disease, spinal cord injury, stroke, ALS (Lou Gehrig's Disease)? Evan Snyder of the Burnham Institute helps define neural stem cells (NSC), explaining that they are relatively inaccessible in the adult patient, but that they seem to benefit from some immunotolerance. It follows that we may be able to use readily available lines of embryonic stem cells for therapy in neurodegenerative disease. Evan reviews current clinical applications for neural stem cells (including as a vehicle for small molecule delivery), and gives his future outlook for neural stem cells. Evan forsees NSCs being used in anti-inflammatory and neuroprotective functions, to deliver tumor killing genes, and to build iPS drug discovery models.
Stem Cell Review: Mesenchymal Stem Cells and Connective Disorders (EP6) (9:32)
<all>Gordana Vunjak-Novakovic of Columbia University gives us an explanation of what mesenchymal stem cells are; adult stem cells that are present in many organs and tissues, and that drive tissue repair. The main sources of mesenchymal stem cells are bone marrow and fat (adipose tissue), although they can be found lesser quantities in muscle, blood, heart, liver, and other tissues. Mesenchymal stem cells can be used to regenerate many different types of tissue, but the most promising clinical applications are in bone, cartilage, ligaments, muscle, neural cells, and striated muscles. Mesenchymal stem cells are thought to repair the heart muscles through revascularization and recruitment of repair cells, but the data does not yet show that they can convert into heart muscle. In a future outlook, Gordana shares with us what she thinks is in the near future of mesenchymal stem cells: well defined cells that can be differentiated predictably, understanding the importance of cell origin on clinical outcome, new FDA friendly delivery routes, more effective functional markers and monitoring, and increasing interdisciplinary collaboration.
Stem Cell Review: Mesenchymal Stem Cells and Connective Disor...
About
Acknowledgements
The entire series is really excellent. Enjoyed the hearing Langer's outlook for potential new treatments.
Thanks